Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Carmel Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02214680
- Locations
- 🇮🇱
Carmel Medical Center, Haifa, Israel
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- Drug: AR-13324 Ophthalmic Solution 0.02%Drug: AR-13324 Ophthalmic Solution 0.02% BIDOther: Placebo
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 756
- Registration Number
- NCT02207621
- Locations
- 🇺🇸
Aerie Pharmaceuticals, Bedminster, New Jersey, United States
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- Drug: AR-13324 Ophthalmic Solution 0.02%Other: Placebo
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 411
- Registration Number
- NCT02207491
- Locations
- 🇺🇸
Aerie Pharmaceuticals, Bedminster, New Jersey, United States
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Rady Children's Hospital, San Diego
- Target Recruit Count
- 26
- Registration Number
- NCT02145884
- Locations
- 🇺🇸
Pediatric and Adolescent Dermatology, Rady Children's Hospital/University of California, San Diego, San Diego, California, United States
Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection
- Conditions
- Intraocular Pressure Change in Intravitreal Injection
- Interventions
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Mashhad University of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT02140450
- Locations
- 🇮🇷
Retina Research Center, Khatam eye Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 100
- Registration Number
- NCT02097719
Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 30
- Registration Number
- NCT02053298
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Flemish Brabant, Belgium
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 89
- Registration Number
- NCT01978600
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
- Conditions
- GlaucomaOcular HypertensionThyroid Eye Disease
- Interventions
- Drug: Prostaglandin Analog
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Stanford University
- Registration Number
- NCT01927406
- Locations
- 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
- Conditions
- Primary Open-Angle Glaucoma (POAG)Ocular Hypertension (OHT)
- Interventions
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Inotek Pharmaceuticals Corporation
- Target Recruit Count
- 101
- Registration Number
- NCT01917383
- Locations
- 🇺🇸
Chiltern, Bristol, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.